Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Randolph Lipchik"'
Autor:
Emily C. O’Brien, Anne S. Hellkamp, Megan L. Neely, Aparna Swaminathan, Shaun Bender, Laurie D. Snyder, Daniel A. Culver, Craig S. Conoscenti, Jamie L. Todd, Scott M. Palmer, Thomas B. Leonard, Wael Asi, Albert Baker, Scott Beegle, John A. Belperio, Rany Condos, Francis Cordova, Joao A.M. de Andrade, Daniel Dilling, Kevin R. Flaherty, Marilyn Glassberg, Mridu Gulati, Kalpalatha Guntupalli, Nishant Gupta, Amy Hajari Case, David Hotchkin, Tristan Huie, Robert Kaner, Hyun Kim, Maryl Kreider, Lisa Lancaster, Joseph Lasky, David Lederer, Doug Lee, Timothy Liesching, Randolph Lipchik, Jason Lobo, Yolanda Mageto, Prema Menon, Lake Morrison, Andrew Namen, Justin Oldham, Rishi Raj, Murali Ramaswamy, Tonya Russell, Paul Sachs, Zeenat Safdar, Barry Sigal, Leann Silhan, Mary Strek, Sally Suliman, Jeremy Tabak, Rajat Walia, Timothy P. Whelan
Publikováno v:
Chest. 157:1188-1198
Background Limited data are available on the association between clinically measured disease severity markers and quality of life (QOL) in idiopathic pulmonary fibrosis (IPF). The study examined the associations between objective disease severity met
Autor:
Aparna C. Swaminathan, Anne S. Hellkamp, Megan L. Neely, Shaun Bender, Luca Paoletti, Eric S. White, Scott M. Palmer, Timothy P. M. Whelan, Daniel F. Dilling, Albert Baker, Scott Beegle, John A. Belperio, Rany Condos, Francis Cordova, Daniel A. Culver, John Fitzgerald, Kevin R. Flaherty, Kevin Gibson, Mridu Gulati, Kalpalatha Guntupalli, Nishant Gupta, Amy Hajari Case, David Hotchkin, Tristan J. Huie, Robert J. Kaner, Hyun J. Kim, Lisa H. Lancaster, Joseph A. Lasky, Doug Lee, Timothy Liesching, Randolph Lipchik, Jason Lobo, Tracy R. Luckhardt, Yolanda Mageto, Prema Menon, Lake Morrison, Andrew Namen, Justin M. Oldham, Tessy Paul, David Zhang, Mary Porteous, Rishi Raj, Murali Ramaswamy, Tonya Russell, Paul Sachs, Zeenat Safdar, Shirin Shafazand, Ather Siddiqi, Barry Sigal, Mary E. Strek, Sally Suliman, Jeremy Tabak, Rajat Walia
Publikováno v:
Annals of the American Thoracic Society. 19(6)
Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
Autor:
Margaret L. Salisbury, Craig S. Conoscenti, Daniel A. Culver, Eric Yow, Megan L. Neely, Shaun Bender, Nadine Hartmann, Scott M. Palmer, Thomas B. Leonard, Albert Baker, Scott Beegle, John Belperio, Rany Condos, Francis Cordova, Daniel Dilling, John Fitzgerald, Kevin R. Flaherty, Kevin Gibson, Mridu Gulati, Kalpalatha Guntupalli, Nishant Gupta, Amy Hajari Case, David Hotchkin, Tristan Huie, Robert Kaner, Hyun Kim, Lisa Lancaster, Joseph A. Lasky, Doug Lee, Timothy Liesching, Randolph Lipchik, Jason Lobo, Tracy Luckhardt (formerly Joao de Andrade), Yolanda Mageto, Numaan Malik, Prema Menon, Lake Morrison, Andrew Namen, Justin Oldham, Tessy Paul, Anna Podolanczuk, Mary Porteous, Rishi Raj, Murali Ramaswamy, Tonya Russell, Paul Sachs, Zeenat Safdar, Shirin Shafazand, Ather Siddiqi, Barry Sigal, Mary Strek, Sally Suliman, Jeremy Tabak, Rajat Walia, Timothy Whelan
Publikováno v:
Annals of the American Thoracic Society
Rationale Two antifibrotic medications, nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) in the US. Few data have been published on the use of these medications in clinical practice. Objective To